| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/29/2005 | EP1546174A2 Methods and compositions for rna interference |
| 06/29/2005 | EP1546173A2 Methods of down regulating target gene expression in vivo by introduction of interfering rna |
| 06/29/2005 | EP1546172A2 Control sequences of the human corin gene |
| 06/29/2005 | EP1546167A1 Compounds that interact with kinases |
| 06/29/2005 | EP1546157A2 PHENYL-AZA-BENZIMIDAZOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION |
| 06/29/2005 | EP1546153A1 Broadspectrum substituted oxindole sulfonamide hiv protease inhibitors |
| 06/29/2005 | EP1546152A1 Epothilone derivatives |
| 06/29/2005 | EP1546151A1 Antidepressant cycloalkylamine derivatives of heterocycle-fused benzodioxans |
| 06/29/2005 | EP1546148A1 Therapeutic compounds based on pyrazolopyridine derivatives |
| 06/29/2005 | EP1546146A1 POLYMORPHIC FORMS OF ZIPRASIDONE HCl AND PROCESSES FOR THEIR PREPARATION |
| 06/29/2005 | EP1546142A2 Indoles having anti-diabetic activity |
| 06/29/2005 | EP1546140A2 Antimicrobial oxazolidinones, process of their preparation, and pharmaceutical compositions containing them |
| 06/29/2005 | EP1546137A1 Benzimidazol-1-yl-thiophene compounds for the treatment of cancer |
| 06/29/2005 | EP1546136A1 Benzopyran derivatives substituted with secondary amines including imidazole, their preparation and pharmaceutical compositions containing them |
| 06/29/2005 | EP1546131A1 Amorphous hydrates of esomeprazole magnesium and process for the preparation thereof |
| 06/29/2005 | EP1546130A1 Novel piperidine derivatives for use in the treatment of chemokine mediated disease states |
| 06/29/2005 | EP1546121A1 Substituted triazine kinase inhibitors |
| 06/29/2005 | EP1546120A2 Pharmaceutical compositions for treatment of parkinson's disease |
| 06/29/2005 | EP1546115A2 Substituted pyrimidines |
| 06/29/2005 | EP1546112A2 Imidazolopyridines and methods of making and using the same |
| 06/29/2005 | EP1546110A2 Compounds active in sphingosine 1-phosphate signaling |
| 06/29/2005 | EP1546105A1 Novel derivatives of pyridylethanol (phenylethyl) amines as inhibitors of cholesterol biosynthesis, processes for their preparation, and pharmaceutical compositions containing them |
| 06/29/2005 | EP1546100A1 New benzoyl piperidine compounds |
| 06/29/2005 | EP1546099A2 3,6-disubstituted azabicyclo 3.1.0 hexane derivatives useful as muscarinic receptor antagonists |
| 06/29/2005 | EP1546098A1 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists |
| 06/29/2005 | EP1546089A2 Aryl and heteroaryl compounds and methods to modulate coagulation |
| 06/29/2005 | EP1546087A1 3-amino-2-hrydroxyalkanoic acids and their prodrugs |
| 06/29/2005 | EP1546086A2 Aminoalcohol derivatives |
| 06/29/2005 | EP1546085A2 Lipophilic diesters of chelating agent for inhibition of enzyme activity |
| 06/29/2005 | EP1546084A1 2,4-dihydroxybenzoic acid derivatives |
| 06/29/2005 | EP1545757A2 Perfluorocarbon emulsions with non-fluorinated surfactants |
| 06/29/2005 | EP1545710A2 Therapeutic use |
| 06/29/2005 | EP1545709A1 Neoadjuvant treatment of breast cancer |
| 06/29/2005 | EP1545708A2 Heterocyclic compound for stimulating or inducing hair or eyelash growth and/or for slowing down hair loss, composition containing same, and uses thereof |
| 06/29/2005 | EP1545643A1 Coated stent |
| 06/29/2005 | EP1545634A2 Method of preparing dry powder inhalation compositions |
| 06/29/2005 | EP1545622A1 Mucoadhesive composition and formulation for solubilization of insoluble drugs and preparation method thereof |
| 06/29/2005 | EP1545621A1 Carrier |
| 06/29/2005 | EP1545619A2 Solution for ungual application |
| 06/29/2005 | EP1545618A1 Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic |
| 06/29/2005 | EP1545599A1 Immunogenic compositions and diagnostic and therapeutic uses thereof |
| 06/29/2005 | EP1545596A2 Use of histamine h4 receptor modulators for the treatment of allergy and asthma |
| 06/29/2005 | EP1545592A1 Combination treatment of cancer using a cancer vaccine and a chemotherapeutic drug |
| 06/29/2005 | EP1545589A1 A method of modulating endothelial cell activity |
| 06/29/2005 | EP1545579A1 Compositions containing peptide copper complexes and phytochemical compounds, and methods related thereto |
| 06/29/2005 | EP1545578A2 Compositions and methods for treating cardiovascular disease |
| 06/29/2005 | EP1545572A2 Conjugates activated by cell surface proteases and therapeutic uses thereof |
| 06/29/2005 | EP1545564A1 Combination preparation of hyaluronic acid and at least one local anesthetic and the use thereof |
| 06/29/2005 | EP1545563A1 Composition and method for use in intestinal cleansing procedures |
| 06/29/2005 | EP1545562A1 Branched alpha-glucans for weight management |
| 06/29/2005 | EP1545561A2 Compositions for treatment of prostate and other cancers |
| 06/29/2005 | EP1545560A2 Inhibition of protein kinase c alpha for treatment of diabetes mellitus and cardiovascular diseases |
| 06/29/2005 | EP1545559A1 Novel use of carbohydrates and compositions |
| 06/29/2005 | EP1545558A2 1, 3, 5-triazines for treatment of viral diseases |
| 06/29/2005 | EP1545557A2 Combination therapies with l-fmau for the treatment of hepatitis b virus infection |
| 06/29/2005 | EP1545555A2 Compositions and methods for treating epithelial and retinal tissue diseases |
| 06/29/2005 | EP1545554A1 Methods and compositions for treating diabetes mellitis |
| 06/29/2005 | EP1545553A1 Use of alkyl phosphocholines in combination with antitumor medicaments |
| 06/29/2005 | EP1545552A1 Combination therapy wherein a serotonin reuptake inhibitor is used |
| 06/29/2005 | EP1545551A1 Delivery of modulators of glutamate-mediated neurotransmission to the inner ear |
| 06/29/2005 | EP1545550A2 Isosorbide mononitrate compositions and methods of their use |
| 06/29/2005 | EP1545549A1 A method of extending the dose range of vitamin d compounds |
| 06/29/2005 | EP1545548A1 The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis |
| 06/29/2005 | EP1545547A1 17&bgr;-ESTRADIOL/LEVONORGESTREL TRANSDERM PATCH FOR HORMONE REPLACEMENT THERAPY |
| 06/29/2005 | EP1545546A1 Treatment of basal ganglia-related movement disorders with 2,3-benzodiazepines |
| 06/29/2005 | EP1545545A2 COMPOUNDS WITH THE BICYCLO 4.2.1 NONANE SYSTEM FOR THE TREATMENT OF i FLAVIVIRIDAE /i INFECTIONS |
| 06/29/2005 | EP1545544A2 Combinations of drugs for the treatment of neoplasms |
| 06/29/2005 | EP1545543A2 Novel tyrosine kinases inhibitors |
| 06/29/2005 | EP1545541A1 Use of a quinazoline derivative for treating lower urinary tract symptoms |
| 06/29/2005 | EP1545540A2 Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist |
| 06/29/2005 | EP1545539A2 Compositions for inducing increased levels of bgr-chemokines and methods of use therefor |
| 06/29/2005 | EP1545538A2 N-biarylmethyl aminocycloalkanecarboxamide derivatives |
| 06/29/2005 | EP1545537A1 Alpha-7 nicotinic receptor agonists and statins in combination |
| 06/29/2005 | EP1545535A2 Treatment of pain by inhibition of p38 map kinase |
| 06/29/2005 | EP1545534A1 Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes |
| 06/29/2005 | EP1545532A2 Heterocyclic compounds |
| 06/29/2005 | EP1545531A1 Use of 5-ht2 receptor antagonists for the treatment of sleep disorders |
| 06/29/2005 | EP1545529A2 Novel tyrosine kinase inhibitors |
| 06/29/2005 | EP1545528A2 Indole-type derivatives as inhibitors of p38 kinase |
| 06/29/2005 | EP1545527A1 Combination comprising a vasculostatic compound and an alkylating agent for the treatmemt of a tumor |
| 06/29/2005 | EP1545524A2 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity. |
| 06/29/2005 | EP1545523A1 3-&-grave;(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES ASP38 MAP KINASE INHIBITORS |
| 06/29/2005 | EP1545522A1 Use of vanilloid receptor antagonists for the treatment of pain |
| 06/29/2005 | EP1545521A2 Compositions and methods for treating sexual dysfunction |
| 06/29/2005 | EP1545520A1 Multifunctional cox-2 inhibitors |
| 06/29/2005 | EP1545519A1 Combination therapy for hyperproliferative diseases |
| 06/29/2005 | EP1545518A1 Broadspectrum 2-amino-benzothiazole sulfonamide hiv protease inhibitors |
| 06/29/2005 | EP1545516A2 Topical formulation comprising at least 5% of metronidazole in white petrolatum and its use in the anal and rectal region |
| 06/29/2005 | EP1545515A1 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors |
| 06/29/2005 | EP1545514A1 Anticoagulant and fibrinolytic therapy using p38 map kinase inhibitors |
| 06/29/2005 | EP1545513A2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases |
| 06/29/2005 | EP1545512A1 Methods for using gold (iii) complexes as anti-tumor and anti-hiv agents |
| 06/29/2005 | EP1545511A1 Combined use of methylphenidate and melatonin for treating attention-deficit hyperactive disorder |
| 06/29/2005 | EP1545510A1 Substituted phenylindoles for the treatment of hiv |
| 06/29/2005 | EP1545509A2 Caspase inhibitors as anticancer agents |
| 06/29/2005 | EP1545508A1 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonist |
| 06/29/2005 | EP1545507A2 Activated checkpoint therapy and methods of use thereof |
| 06/29/2005 | EP1545506A1 Use of angelicin and of its structural analogues for the treatment of thalassemia |
| 06/29/2005 | EP1545504A2 Non-psychotropic cannabinoids for prevention of cognitive impairment |
| 06/29/2005 | EP1545503A2 Pharmaceuticals formulations and methods for modified release of statin drugs |